04 Jan 2013, BioSpectrum Bureau , BioSpectrum
Singapore: US-based GoBalto, which makes cloud-based software to support the clinical trials of pharmaceutical companies, raised funding worth $12 million in a Series B round from EDBI.
EDBI, which is the investing arm of Singapore's Economic Development Board, had recently been joined by Qualcomm Ventures; returning investors, Aberdare Ventures, and West Health Investment Fund.
GoBalto CEO, Mr Jae Chung, said that the company raised a total of $21 million from investors, and that its valuation is "in the tens-of-millions." Although GoBalto aims to create several products to simplify clinical-trials workflow, its first product is focused on the people that are hired by pharma firms to find human-trial subjects for drug studies. Mr Chung further revealed that said the country's five top pharma companies and five top contract research organizations (CROs) are users of their platform.